Parry-Romberg Syndrome Market Overview, Size, Share, Analysis

Q: Name the notable players of the global Parry-Romberg syndrome market?

Medtronic, Johnson &amp; Johnson Services, Inc., AstraZeneca plc Biogen, Inc., Pfizer, Inc., Sanofi-Aventis, DePuy Synthes, GlaxoSmithKline, Inc., Taj Pharmaceuticals Ltd., Abbott, and Immediate Media Company Ltd. are major players of the global Parry-Romberg syndrome market.. Read More

Parry-Romberg Syndrome Market Scenario

The Parry-Romberg Syndrome Market is expected to reach USD 923.3 Million by 2030 at 9.6% CAGR during the forecast period 2022-2030. Parry-Romberg syndrome is also known as progressive hemifacial atrophy. It is a rare disease, which is characterized by the shrinking and degeneration of the tissues beneath the skin.

Parry-Romberg Syndrome Market

The changes and deterioration spread slowly and it occurs on one side and rarely extends to other parts of the body. General symptoms, includes facial changes, which involves the tissues above the upper jaw or between the nose and the upper corner of the lip and subsequently progress to the mouth, areas around the eye, the ear, and the neck. Currently, no cure and treatments are available for the parry-Romberg syndrome.

Increasing prevalence of skin diseases, neurological abnormalities, and eye defects are the major driving factors for the growth of the market during the forecast period. Moreover, oral diseases also boost the market growth as the tissues of mouth, including the tongue, gingiva, teeth, and soft palate are commonly involved in Parry-Romberg syndrome.

According to the Centers for Disease Control And Prevention, skin diseases is the most common in the US and over 7% of skin related diseases that are tracked by skin cancer registries are adding fuel to the market growth.

According to the WHO, millions of people worldwide are affected by neurological abnormalities or disorder. More than 6 million people die because of stroke each year; over 80% of deaths take place in low and middle income countries, which will boost the market growth in developing regions.

On the other hand, high cost of current treatment methods, and long duration for complete cure, for instance, it takes one-two years for facial growth and after facial growth the surgery is proceeded, which may hamper the market growth.

Parry-Romberg Syndrome Market Segmentation

The global Parry-Romberg syndrome market is segmented on the basis of diagnosis, treatment, and end user.

On the basis of diagnosis, the market is segmented into physical examination, MRI, serum test, and other.

On the basis of treatment, the market is categorized into drug treatment, surgery, and others. The drug treatment is further segmented into methotrexate, corticosteroids, cyclophosphamide, azathioprine, and others. The surgery is sub-segmented into orthognathic surgery, microsurgical reconstructive surgery, and others.

On the basis of end user, the market is segmented into hospitals & clinics, physical therapists, and others.

Parry-Romberg Syndrome Market Key Players

Some of the key players in parry-romberg syndrome market are:

DePuy Synthes (U.S.)

Johnson & Johnson Services, Inc. (US)

Medtronic (Ireland)

Abbott (US)

Immediate Media Company Ltd. (US)

Taj Pharmaceuticals Ltd.

Pfizer, Inc.

Sanofi-Aventis

Biogen, Inc.

GlaxoSmithKline, Inc.

AstraZeneca plc.

Figure: Global Parry-Romberg Syndrome Market, by Region, 2016 (%) Parry-Romberg Syndrome Market-

Source: World Health Organization, Centers for Disease Control and Prevention, expert interview market research future analysis, annual report, white paper, company presentation

Parry-Romberg Syndrome Market Regional Analysis

The Americas dominates the global Parry-Romberg syndrome market owing to the presence of huge geriatric population, increasing number of patient with neurological disorder, eye related disorders. Moreover, high healthcare speeding, advanced hospitals infrastructures, availability of skilled healthcare professional are boosting the growth of the market.

Europe accounts for the second largest Parry-Romberg syndrome market across the globe owing to increasing government support for research & development, and increasing investment in healthcare. The countries such as France, and Germany investing in the healthcare to develop new diagnosis and treatment methods for rare diseases, which will boost the market growth. As per Organization for Economic Co-operation and Development (OECD), the share of GDP to health spending in Germany was 11.0% in 2013, compared with a share of GDP was up from 10.8% in 2012, which is responsible for the growth of the market in this region.

Asia Pacific has the fastest growing market, increasing government support for research & development, increasing prevalence of skin diseases, eye related diseases, and huge population base and rapidly developing economy drives the growth of the market in this region. Developing countries in this region are focusing more in the development of healthcare domain for instance country such as India.

The Middle East & Africa is expected to show the least market share due to less availability of medical facilities, and less development in healthcare domain.

Intended Audience

Pharmaceutical Companies

Medical Devices Manufacturer

Research and Development (R&D) Companies

Market Research and Consulting Service Providers

Potential Investors

Research Methodology

Source: World Health Organization, Centers for Disease Control and Prevention, expert interview market research future analysis, annual report, white paper, company presentation

Report Attribute/Metric	Details
Market Size	USD 923.3 Million
CAGR	9.6%
Base Year	2021
Forecast Period	2022-2030
Historical Data	2020
Forecast Units	Value (USD Million)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered	Diagnosis, Treatment and End User
Geographies Covered	North America, Europe, Asia-Pacific, and Rest of the World (RoW)
Key Vendors	DePuy Synthes (U.S.), Johnson & Johnson Services, Inc. (US), Medtronic (Ireland), Abbott (US), Immediate Media Company Ltd. (US), Taj Pharmaceuticals Ltd., Pfizer, Inc., Sanofi-Aventis, Biogen, Inc., GlaxoSmithKline, Inc., and AstraZeneca plc.
Key Market Opportunities	The Americas dominates the global Parry-Romberg syndrome market owing to the presence of huge geriatric population, increasing number of patient with neurological disorder, eye related disorders. In Europe Region, Increasing government support for research & development, and increasing investment in healthcare In Asia Pacific, increasing government support for research & development, increasing prevalence of skin diseases, eye related diseases, and huge population base and rapidly developing economy drives the growth of the market
Key Market Drivers	Increasing prevalence of cancer Increasing investment of biotechnology and pharmaceutical industries in R&D, Rising need for the better diagnostic methods

Parry-Romberg Syndrome Market Highlights:

Frequently Asked Questions (FAQ) :

What is the expected growth rate of the global Parry-Romberg syndrome market?

Parry-Romberg syndrome market is expected to register 9.6% CAGR from 2022 to 2030.

Which is the biggest driver of the global Parry-Romberg syndrome market?

Parry-Romberg syndrome market is driven by rising incidence of skin conditions, neurological disorders, and eye defects.

What factors can restrain the global Parry-Romberg syndrome market?

Long waiting times for cures and high costs for treatments are factors which can hamper the global Parry-Romberg syndrome market.

Which region can dominate the global Parry-Romberg syndrome market?

The Americas can dominate the global Parry-Romberg syndrome market till 2030.

Name the notable players of the global Parry-Romberg syndrome market?

Medtronic, Johnson & Johnson Services, Inc., AstraZeneca plc Biogen, Inc., Pfizer, Inc., Sanofi-Aventis, DePuy Synthes, GlaxoSmithKline, Inc., Taj Pharmaceuticals Ltd., Abbott, and Immediate Media Company Ltd. are major players of the global Parry-Romberg syndrome market.

Leading companies partner with us for data-driven Insights

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
	Single User	$ 4,950
	Multiuser License	$ 5,950
	Enterprise User	$ 7,250
Compare Licenses

FEATURES	LICENCE TYPE
FEATURES	Single User	Multiuser Licence	Enterprise User
Price	$ 4,950	$ 5,950	$ 7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout The Organization.
Free Customization
Direct access to the Analyst
Deliverable Format
Deliverable Format
Platform Access
Discount on Your Next Purchase	10%	15%	10%
Printable Versions

Parry-Romberg Syndrome Market Research Report Information: By Diagnosis (Physical Examination, MRI Scan, Serum Test, and others), By Treatment (Drug Treatment, Surgery, others), and By End User (Hospitals & Clinics, Physical Therapists, others) - Forecast till 2030